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ABSTRACT 
Muscular Dystrophy (MD) is characterized by varying severity and time-of-onset 
by individuals afflicted with the same forms of MD, a phenomenon that is not well 
understood. MD affects 250,000 individuals in the United States and is characterized by 
mutations in the dystroglycan complex. gmppb encodes an enzyme that glycosylates 
dystroglycan, making it functionally active; thus, mutations in gmppb cause 
dystroglycanopathic MD1. The zebrafish (Danio rerio) is a powerful vertebrate model for 
musculoskeletal development and disease. Like human patients, gmppb mutant zebrafish 
present both mild and severe phenotypes. In order to understand the molecular mechanisms 
involved, we performed high-throughput RNA Sequencing (RNA-Seq) and small RNA 
Sequencing at 4 and 7 days-post-fertilization (dpf) in mild and severe gmppb mutants and 
controls. We hypothesize that variable phenotypes in gmppb mutants are due to differences 
in gene regulation; therefore, we identified differentially expressed (DE) long non-coding 
RNAs (lncRNAs) and microRNAs (miRNAs) - both potent genetic regulators. We 
identified “MD-relevant” DE Ensembl-annotated genes involved in cell cycle regulation, 
the immune response, neural development and maturation, and skeletal muscle atrophy. 
We identified DE miRNAs that regulate these DE genes in the 4dpf severe mutants – 
identifying 55 of these interactions. We utilized a novel method of visualizing gene 
expression networks by generating co-expression networks of miRNAs and subsequently 
removing miRNA nodes to identify important miRNAs. We identified 95 potential 
lncRNAs for further analysis. By integrating analyses of both coding and non-coding 
genes, we contributed towards the understanding of the molecular mechanisms of 
Dystroglycanopathy, highlighting potential phenotypic modulators.
 
iii 
 
ACKNOWLEDGEMENTS 
None of this work would have been possible without the support of countless 
professors, teachers, and other mentors who believed in me, inspired me, and pushed me 
to reach out of my comfort zone. My love of Molecular Biology first sprouted my 
sophomore year in Honors Biology with Mr. Rand. As both my science professor and Cross 
Country/Track Coach, he challenged me to excel in the classroom and beyond. He was the 
reason I applied to my first research internship at the University of Maine. That is where I 
was first mentored by Dr. Eric Gallandt and Sonja Birthisel who nurtured me and 
encouraged me to strive to become a more independent thinker. Not to mention, Sonja was 
the first to introduce me to R! 
Many thanks to Dr. Molloy who was a pivotal component of my freshman year 
(and beyond). She encouraged me to strive for personal growth, become a better team 
member, let go of my competitiveness (through bribing me with hot cocoa), and fearlessly 
make mistakes - as long as I learned from them. 
To Dr. King who took a chance on me and allowed me to join his lab after getting 
rejected from every single summer internship I applied for freshman year. I’ve been so 
blessed to have your support all throughout my undergraduate - you’ve challenged me to 
strive for every opportunity, whether I think I have a chance or not. Being a part of your 
lab has been my favorite experience during this time and has catalyzed so much personal 
and scientific growth - not to mention it made me fall in love with computer science! I can 
only aspire to mentor in the way you do one day.  
 
iv 
 
Thanks to Dr. Jason Thomas, Jennifer Lipps, and Zeus whose support has remained 
unwavering and have challenged me to defend the defenseless and stand up for what I 
believe in.  
Thanks to Dr. Aadel Chaudhuri, Pradeep Chauhan, and Peter Harris. Washington 
University had such a profound effect on my academic path, and I cannot thank you enough 
for allowing me to explore all the opportunities there - and mentoring and supporting me 
throughout. 
Thanks to Nives Dal Bo-Wheeler for her unwavering support of the students at the 
University of Maine - we are so incredibly lucky to have you!  
Many thanks to the Honors College. The Honors College and the liberal arts education I 
received through it, completely changed my view of the world around me - and I cannot 
thank you all enough for that. Dr. Ladenheim and Dr. Amar have helped me pursue my 
dreams and share my honors experience with others. Furthermore, Dr. Ladenheim has been 
a constant source of support and encouragement - as well as a phenomenal reading list 
advisor.  
Finally, to my parents who have supported me in everything I do and loved me 
unconditionally.  
 
 
 
  
 
v 
 
TABLE OF CONTENTS 
 
1. INTRODUCTION .......................................................................................................... 1	
1.1 Muscular Dystrophy ........................................................................................... 1	
1.2 Dystroglycanopathies ......................................................................................... 3	
1.3 Skeletal Muscle Structure ................................................................................... 4	
1.4 Zebrafish as a model organism for Skeletal Muscle Development .................... 7	
1.5 Zebrafish as a model organism for dystroglycanopathy .................................... 7	
1.6 A gmppb mutant model of dystroglycanopathy ................................................. 8	
1.7 Long non-coding RNAs ................................................................................... 10	
1.8 MicroRNAs ...................................................................................................... 11	
1.9 RNA sequencing to measure gene expression ................................................. 12	
1.10 MiRNA Network Attack ................................................................................ 14	
1.11 MiRNA gene target analysis .......................................................................... 15	
1.12 Research Objectives ....................................................................................... 16	
2. MATERIALS AND METHODS:................................................................................. 17	
2.1 Overview of the experimental design ............................................................... 17	
2.2 RNA extraction ................................................................................................. 18	
2.3 RNA sequencing and small RNA Sequencing ................................................. 19	
2.4 RNA sequencing annotation workflow ............................................................ 20	
2.5 Small RNA sequencing workflow .................................................................... 23	
2.5 Splicing analysis of gmppb mutants ................................................................. 23	
2.6 Identification and characterization of differentially expressed novel and 
previously annotated lncRNAs and nearby genes .......................................... 25	
2.7 Characterization of differentially expressed protein coding genes .................. 25	
2.8 Characterization of differentially expressed miRNA and network attack ....... 26	
2.9 miRNA target analysis ..................................................................................... 26	
2.10 Comparison of gene expression to cardiac regeneration ................................ 27	
3. RESULTS ..................................................................................................................... 28	
3.1 mRNA sequencing of gmppb mutants .............................................................. 28	
3.1.1 Identifying differentially expressed Ensembl annotated genes. .............. 28	
 
vi 
 
3.1.2 Identifying novel transcripts for lncRNA analysis. ................................. 35	
3.2 Small RNA sequencing of gmppb mutants to identify differentially expressed 
miRNAs .......................................................................................................... 36	
3.3 MiRNA co-expression networks ...................................................................... 37	
3.4 miRNA target prediction at 4dpf in the gmppb severe mutants ....................... 40	
3.5 Splicing analysis of gmppb severe mutants ...................................................... 44	
4. DISCUSSION & FUTURE DIRECTIONS ................................................................. 48	
4.1 mRNA sequencing of gmppb mutants .............................................................. 48	
4.1.1 Differences in number of differentially expressed genes confirms 
differences in gmppb mild and severe mutants. ..................................... 48	
4.1.2 Gene Ontology characterization reveals phenotype-relevant genes. ....... 49	
4.1.4 Identifying novel transcripts for lncRNA analysis. ................................. 53	
4.2 Small RNA sequencing of gmppb mutants to identify differentially expressed 
miRNAs .......................................................................................................... 54	
4.3 MiRNA co-expression networks reveal miRNAs that contribute towards 
network structural integrity. ............................................................................ 55	
4.4 MiRNA target prediction at 4dpf in the gmppb severe mutants reveals an 
overlapping network of miRNAs regulating a cohort of Ensembl annotated 
genes ............................................................................................................... 56	
4.5 Splicing analysis: gmppb severe mutants are characterized by two categories of 
mutations ......................................................................................................... 58	
BIBLIOGRAPHY ............................................................................................................. 61	
APPENDICES .................................................................................................................. 69	
APPENDIX A: COMPARISON OF MUSCULAR DYSTROPHY TYPES ................... 70	
APPENDIX B: SCRIPTS ................................................................................................. 71	
B1 Identifying predominantly expressed miRNA .................................................. 71	
B2 Repeat Masker analysis to identify candidate lncRNAs ................................... 72	
AUTHOR’S BIOGRAPHY .............................................................................................. 74	
 
  
 
vii 
 
LIST OF FIGURES 
Figure 1. The dystroglycan complex consists of multiple protein subunits that connect the 
extracellular matrix to the cellular cytoskeleton. Figure taken from Barresi, 20182. 2 
Figure 2.  Skeletal Muscle Structure12. 6 
Figure 3. Differences in severity of MD phenotypes in gmppb mutant zebrafish at two 
days post-fertilization (2df). Control is gmppb wild type whereas mild and severe 
are homozygous gmppb mutants. The bottom figure of each zebrafish shows the 
birefringence which indicates skeletal muscle organization3. Figures courtesy of C. 
Henry lab. 9 
Figure 4. Experimental overview of RNA Sequencing and small RNA Sequencing in 
gmppb+/- controls and gmppb-/- mutants exhibiting mild or severe phenotypes. 17 
Figure 5. Gene annotation workflow for identifying differentially expressed ensembl 
annotated genes and unannotated novel transcripts. 22 
Figure 6. From mRNA sequencing, a list of differentially expressed gene transcripts 
defined by a threshold of p<0.05, or adjusted p<0.05 were subset. Those with 
Ensembl annotations are included in this figure. The table shows the number of 
differentially expressed genes in each sample according to the threshold definition 
of differentially expressed. 28 
Figure 7. Venn diagrams of differentially expressed Ensembl annotated genes. Panel A 
includes genes with unadjusted p-values < 0.05 while panel B includes genes with 
adjusted p-values < 0.05. Regions of overlap indicates genes that are differentially 
expressed at the multiple specified timepoints or phenotypes. Percentages are 
included to indicate the number of genes in each category over the total number of 
differentially expressed genes. 29 
Figure 8. Identification of potential lncRNAs. A. Total genes (blue = ensembl annotated, 
yellow = unannotated) with adjusted p-values less than 0.05 in 4dpf severe mutants. 
B. Genes from panel A with Log2FC > 1 or < -1. C. Novel genes from panel B with 
Coding Potential < 0.38 as determined by CPAT. D. Novel Genes from panel C with 
< 50% repetitive bases. 35 
Figure 9. Number of differentially expressed miRNA as indicated by adjusted p-value < 
0.05 and unadjusted p-values < 0.05. 36 
Figure 10. Overlap of differentially expressed miRNAs. A: miRNAs that are 
differentially expressed according to an unadjusted p-value < 0.05. B: miRNAs that 
are differentially expressed according to an adjusted p-value < 0.05. Venn diagrams 
made with Venny 2.0. 37 
 
viii 
 
Figure 11. Characteristic path length upon removal of individual nodes in miRNA 
expression.  miRNAs in each plot that upon removal cause relatively large changes 
in path length are labeled. Resultant characteristic path length upon removal of 
miRNA nodes in sibling 4dpf and 7dpf co-expression network (A), mild 4dpf and 
7dpf co-expression network (B), and severe 4dpf and 7dpf co-expression network 
(C). D has all three networks overlaid into one graph. 38 
Figure 12. Network size upon removal of nodes from sibling (black), mild (blue), and 
severe (red) 4dpf and 7dpf co-expression networks. 39 
Figure 13. MiRNA and mRNA target interactions at 4dpf in gmppb severe mutants. A: 
Each of the green nodes is an upregulated miRNA (unadjusted p <0.05); each of the 
red nodes are downregulated ensembl annotated genes (adjusted p < 0.05). B: Green 
nodes are upregulated ensembl annotated genes, red nodes are downregulated 
miRNAs. Edges are denoted by arrows and show miRNAs targeting mRNAs based 
on TargetScanFish data. The width of the edges is based on the context score of the 
interaction between the miRNA and mRNA. 41 
Figure 14. Stop cassette structure. The stop cassette consists of a left gmppb homology 
domain and a right gmppb homology domain, with the stop codon region containing 
stop codons in every reading frame. Shown in light blue is the where the regions of 
homology share sequence with gmppb. 44 
Figure 15. Partial double insertion mutation structure. A. In three of the 18 sequenced 
mutants, the stop cassette insertion consisted of incorporation of a partial stop 
cassette followed by a full stop cassette. B. Shown is a simple pictorial 
representation of the mutation with a subset of the left homology, a full stop 
cassette, a portion of the right homology, a partial stop cassette, and then the right 
homology region. 45 
Figure 16. “TG Gap” mutation consists of an 8 base pair deletion between the left and 
right homology domains of gmppb. 46 
Figure 17. Characterization of reads from RNA Sequencing. The number of reads were 
expressed as counts per million (CPM). A: Results from searching for 
“TAGTGTTACCTT” and “AAGGTAACACTA”, sequences representing four 
nucleotides of the right homology of the stop cassette (SC) and 4nts of the stop 
codons of the SC to either end. B: Results from searching for an additional sequence 
in the resulting reads from A, “GGAGGC” a sequence present in exon 2 of gmppb 
and “GTCCGT”, a sequence present in exon 3 of gmppb. This step ensures that the 
reads come from gmppb.  C: In a similar fashion to graph A, a sequence, this time 
representing the TG Gap mutation identified from the PCR of gmppb mutants, was 
searched for. D: Number reads with exons 2 and 3 subsequences. 47 
 
 
 
ix 
 
LIST OF TABLES 
Table 1. Genes Associated with Dystroglycanopathic Muscular Dystrophy10. 4 
Table 2. Ten most differentially expressed Ensembl annotated genes. 31 
Table 3.  Differentially expressed (unadj p <0.05) genes with selected Gene Ontology 
annotations at 4 and 7dpf in the severe mutants. 32 
Table 4.  Differentially expressed (adjusted p <0.05) genes with selected Gene Ontology 
annotations at 4 and 7dpf in the severe mutants. 34 
Table 5. Number of nodes in miRNA co-expression networks. 37 
Table 6. miRNAs that upon removal cause gaps in characteristic path length 39 
Table 7. Upregulated mRNA targets of downregulated miRNAs in 4dpf Severe mutants.
 42 
Table 8. Downregulated mRNA targets of upregulated miRNAs in 4dpf Severe mutants.
 43 
 
 
1 
 
1. INTRODUCTION 
1.1 Muscular Dystrophy 
Muscular Dystrophy (MD) is a group of debilitating musculoskeletal disorders that 
affects 250,000 individuals in the United States1. At the moderate end, MD symptoms can 
develop during late adulthood and be characterized by weak, but still functional muscles 
(Appendix A, Table A1). At the more severe end of the spectrum, symptoms can develop 
prenatally and consist of severe brain and eye abnormalities which often lead to miscarriage 
of the developing fetus2. To some extent, symptoms are related to the form of MD an 
individual has. There are nine main forms of MD (Appendix A, Table A1); each caused by 
mutations in dozens of different genes encoding the protein subunits of the dystroglycan 
complex, or in some cases, mutations in enzymes involved in post-transcriptional 
modification of these subunits.  
Mutations in any of the protein components of the dystroglycan complex can cause 
MD (Figure 1). This complex is essential in skeletal muscle as it provides structural 
stability to the sarcolemma by linking the cells to one another, resulting in long, robust 
fibrils. The dystroglycan complex consists of the transmembrane β-dystroglycan complex 
which is bound to ɑ-dystroglycan. On the intracellular end of β-dystroglycan, dystrophin 
subunits polymerize and are eventually linked to the cytoskeleton. The sarcoglycans 
provide increased stability to the complex and help mediate the strong connection between 
ɑ and β dystroglycan3. ɑ-dystroglycan is a ligand for laminin 2 which links the complex to 
the extracellular matrix. This interaction is crucial during muscle contraction, where 
impediment of this complex leaves muscle fibers more susceptible to damage. Two of the 
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most common forms of MD, Becker MD (BMD) and Duchenne's MD (DMD) are caused 
by mutations in dystrophin, the intracellular tether that links the dystroglycan complex to 
the cytoskeleton. Generally, the more severe phenotype of DMD is attributed to genetic 
mutations that results in premature termination of dystrophin whereas BMD is the result of 
missense or frameshift mutations which do not majorly impact the length of the protein4–6. 
As stated previously, mutations in any of these protein subunits can lead to MD; however, 
mutations in genes associated with post-transcriptional modification of these subunits can 
also cause MD. 
 
Figure 1. The dystroglycan complex consists of multiple protein subunits that connect the 
extracellular matrix to the cellular cytoskeleton. Figure taken from Barresi, 20182.  
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1.2 Dystroglycanopathies 
Dystroglycanopathies include two forms of MD: Congenital MD (CMD) and Limb 
Girdle MD (LGMD). They are caused by improper glycosylation of the protein subunits 
composing the dystroglycan complex, a post-transcriptional modification. The ɑ and β 
dystroglycan subunits are derived from the same gene - the transcribed dystroglycan 
mRNA is split into two mRNAs prior to translation7. Mutations in dystroglycan lead to 
decreased muscle fiber strength, similar to the result of mutations in dystrophin. Besides 
being involved in muscle fiber strength, the α-dystroglycan subunit is also involved in 
signaling pathways. Under certain conditions, it inhibits survival signaling in muscle cells 
via caspase activation, leading to muscle cell apoptosis8, another characteristic result of 
MD. In addition, the dystroglycan complex serves as a node in the signal transduction 
pathway that leads to activation of STAT3 (signal transducer and activator of transcription 
3).  STAT3 plays an important role in regulating satellite cell self-renewal, and inducing 
expression of Interleukin 6, a cytokine that acts as an anti-inflammatory myokine9. Thus, 
improper formation of dystroglycan leads to multiple abnormal regulatory pathways. As 
stated before, for dystroglycan to be functional, it must be glycosylated. There are 17 genes 
many of which are enzymes that have been implicated in dystroglycan glycosylation (Table 
1). Even within dystroglycanopathies, the symptom severity and time of onset varies 
greatly - even within individuals with mutations in the same genes, a perplexity that is not 
well understood2. This phenotypic complexity warrants further studies to understand the 
genetic basis behind these differences.  
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Table 1. Genes Associated with Dystroglycanopathic Muscular Dystrophy10. 
 
 
1.3 Skeletal Muscle Structure  
Skeletal muscle is one of the three major muscle types. It consists of striated muscle 
tissue controlled voluntarily via the somatic nervous system. Skeletal muscle is attached to 
bones via bundles of collagen and its rigidity comes from the fractal arrangement of 
subunits (Figure 2). The muscle is composed of multiple muscle fascicles lined up in a 
parallel fashion, wrapped in a connective tissue sheath called the epimysium, which is 
surrounded by an outer connective tissue layer, called the fascia. The muscle fascicles are 
composed of multiple muscle fibers surrounded by another connective sheath called the 
perimysium; blood vessels and nerves are dispersed between the fascicles. The muscle 
fibers are cylindrical, multinucleated cells, with a sarcolemma cell membrane that result 
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from fusion of multiple cells during myogenesis, or muscle development. The muscle 
fibers are surrounded by another connective tissue layer called the endomysium. Muscle 
fibers themselves consist of multiple myofibrils aligned in an organized parallel fashion 
with abundant mitochondria dispersed throughout. The myofibrils are composed of 
myofilaments, sarcomere-based structures composed of thin actin filaments and thick 
myosin filaments that shrink for muscle contraction and stretch for muscle relaxation11,12.  
Neuromuscular junctions (NMJ) are sites where a motor neuron meets a muscle fiber. 
Excitation signals travel from the brain down the neuron to the muscle fiber. The muscle 
fiber is surrounded by the sarcoplasmic reticulum, which upon exposure to acetylcholine 
provided by the action potential, opens up sodium channels that allow for an influx of 
sodium into the cell. This signal propagates, causing voltage sensitive calcium channels to 
open, allowing for an influx of calcium into the myofilaments which allows myosin to 
bring the actin filaments closer together via the sliding filament model, initiating muscle 
contraction13.  
Exercise and repeated use of muscles leads to structural changes in the muscle 
fibers. Some of these changes include angiogenesis - formation of more extensive capillary 
networks to meet the oxygen needs of the muscle, increased production of mitochondria, 
hypertrophy - increasing the diameter of the muscle fibers, and changes in the proportions 
of slow oxidative (SO), fast oxidative (FO), and fast glycolytic (FG) fibers14.  Strenuous 
exercise can cause muscle fiber damage via overstretching of sarcomeres, leading to 
inflammation and damage to the connective tissue layers of the muscle.  Overall, this leads 
to necrosis, that peaks 48 hours after strenuous activity or overuse. Healthy exercising 
persons undergo this process constantly and can regenerate the damaged muscle fibers 
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through satellite cell proliferation and differentiation. Satellite cells are found underneath 
the basal lamina of muscle fibers15 and begin proliferating when exposed to signals derived 
from damaged fibers and infiltrating immune cells. Following proliferation, they 
differentiate into myoblasts which through fusion replace the damaged muscle fibers16. 
Notch signaling is thought to play an important in role in stimulating this process17. In 
individuals with Muscular Dystrophy, regeneration after muscle fiber damage is impeded 
due to satellite cell depletion16.  
 
Figure 2.  Skeletal Muscle Structure12.  
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1.4 Zebrafish as a model organism for Skeletal Muscle Development  
The zebrafish (Danio rerio) is a well-established vertebrate model organism that 
has been used to study neurological diseases including Alzheimer’s and Parkinson’s 
disease as well as musculoskeletal disorders. Zebrafish development is much faster than in 
mice models, and they are cheaper and require less physical space to grow. Zebrafish have 
70% of genes conserved with humans18. Structurally, they have many of the same organs 
and systems that humans have, including a heart, brain, spinal cord, various types of 
musculature, blood, and both an innate and adaptive immune system. Several methods, 
including CRISPR/Cas9, can be used to develop transgenic zebrafish where specific 
mutations can be introduced.  
Zebrafish skeletal muscle structure closely resembles that of humans, making them 
good models for musculoskeletal development. Using zebrafish, precursors to slow and 
fast twitch muscles have been identified and observed during development19. Additionally, 
the interaction between the muscle fibers attachment to the cytoskeleton and the 
extracellular matrix and how it relates to muscle rigidity has been determined20, and the 
molecular mechanism of muscle cell contraction has been elucidated21. Of course, these 
are but a few of the discoveries that zebrafish models of skeletal muscle development have 
unraveled.  
1.5 Zebrafish as a model organism for dystroglycanopathy 
To better understand the complexity of dystroglycanopathy, accurate and useful 
model organisms are required. Most models for MD are mice models. In fact, mouse 
models of dystroglycanopathy exist that accurately represent the phenotypes of patients. 
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These mutants have mutated genes earlier presented in Table 1 including large22, pomt123, 
dag1 24, and others. Unfortunately, similar zebrafish glycosylation mutants are still in 
development; current mutants exist for ispd25, but most mutants are created transitively 
using morpholino knockdowns. While morphants are useful in some contexts, the need 
exists for stable zebrafish lines. A zebrafish model for Duchenne’s Muscular Dystrophy 
(DMD) with mutated dystrophin exist which displays similar phenotypes as DMD human 
patients, including myofiber atrophy, immune cell infiltration into skeletal muscle, and 
abnormally shaped myofibrils20. Therefore, zebrafish have the potential to be an accurate, 
convenient, and fast-growing model for dystroglycanopathy research. The Henry lab at the 
University of Maine has been working on developing zebrafish with mutations in each of 
the genes listed in Table 1.  
1.6 A gmppb mutant model of dystroglycanopathy 
One of the dystroglycanopathic zebrafish models that has been successfully 
established by the Henry lab is a GDP-mannose Pyrophosphorylase (gmppb) mutant. The 
protein product of gmppb catalyzes the conversion of mannose-1-phosphate and GTP to 
GDP-mannose, a reaction involved in the production of N-linked oligosaccharides. These 
sugars are produced in the Golgi Apparatus and then are subsequently attached to a-
dystroglycan as a post-translational modification.  Mutations in gmppb have been 
associated with Limb Girdle MD and Congenital MD due to hypo-glycosylated α-
dystroglycan26. As of 2018, 81 MD patients worldwide have been described with mutated 
gmppb2,26–28. The low number of documented cases may be based on a lack of screening. 
Astrea et al. tested this hypothesis, screening 73 Italian individuals with genetically 
unidentified forms of Congenital MD and α-dystroglycan hypoglycosylation for gmppb 
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mutations2. Thirteen cases of gmppb biallelic mutations were identified in which seven 
novel mutations in gmppb were revealed: all leading to highly variable phenotypes from 
congenital clubfoot, seizures, neurodevelopmental abnormalities and autism spectrum 
disorders2.  
Zebrafish gmppb mutants were engineered by the Henry Lab using a CRISPR/Cas9 
system previously described by Gagnon et. al29. Primers were designed using 
CHOPCHOP29 with the intention of inserting a stop cassette in exon three of gmppb. 
CRISPR/Cas9 was performed in one cell stage AB zebrafish embryos (F0 generation) and 
the resulting fish were crossed to form the F1 generation which was similarly crossed to 
form the F2 generation. Data presented in this thesis is from the F2 generation and 
subsequent generations. Generation of the mutant line was done by the the Henry Lab30. 
The Henry Lab’s gmppb mutant presents variable phenotypes, in a similar manner to 
human patients with gmppb mutations. The mutants display muscular atrophy, decreased 
muscle density, and disorganized muscle fibers (Figure 3), and can be classified by those 
with either severe or mild phenotype.   
 
Figure 3. Differences in severity of MD phenotypes in gmppb mutant zebrafish at two days 
post-fertilization (2df). Control is gmppb wild type whereas mild and severe are 
homozygous gmppb mutants. The bottom figure of each zebrafish shows the birefringence 
which indicates skeletal muscle organization3. Figures courtesy of C. Henry lab. 
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1.7 Long non-coding RNAs 
LncRNAs are regulatory genes located in regions of the genome previously termed 
“junk DNA” that provide a novel lens to view physiological processes and diseases31. 
These genes are transcribed into RNA, but not translated; thus, existing as RNA 
intermediates that regulate gene expression through diverse, uncharacterized mechanisms 
in both the nucleus and cytoplasm. For example, the lncRNA XIST directly interacts with 
DNA, signaling the condensations of one of the X-chromosomes in mammalian females, 
forming a barr body31. LncRNAs can also form secondary and tertiary structures that aid 
in their mechanism of action. The lncRNA HOTAIR is a repressor of tumor repressor and 
metastasis genes. It forms an intricate structure consisting of 56 helical segments, 38 
terminal loops, 34 internal loops, and 19 junction regions32.  LncRNAs are also able to 
regulate gene expression by hybridizing with mRNA gene transcripts to signal mRNA 
degradation, decreasing protein expression31. For example, the lncRNA α-HIF is a natural 
antisense transcript of hypoxia-inducible factor 1 alpha (HIF-1α) that binds to HIF-1a 
based on sequence similarity. When it does so, it exposes AU-riches elements present in 
the 3’UTR of the HIF-1α mRNA, increasing the speed of mRNA degredation33. Alterations 
in protein expression becomes much more complex when one considers the plethora of 
interactions that a single protein can have, thus lncRNAs act as essential nodes in a complex 
map of physiological processes. LncRNAs are considered the most functionally diverse 
and numerous classes of RNAs34, yet their regulatory roles in the majority of processes and 
diseases is not well understood. They even have proposed hypothetical roles in MD35, but 
have yet to be experimentally investigated in this context.  
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1.8 MicroRNAs 
MicroRNAs (miRNAs) are another class of non-coding regulatory genes, who, in 
contrast to lncRNAs, have well understood mechanisms of action. Additionally, miRNAa 
are more conserved than lncRNAs with humans, and over 400 miRNAs are annotated by 
Ensembl36 in the zebrafish. The biogenesis of miRNAs follows a conserved processing 
pathway. Following transcription by RNA Polymerase II or III, the pri-miRNA is cleaved 
by Drosha, a ribonuclease, to form a pre-miRNAs which is then able to exit the nucleus via 
export by Exportin 5/RanGTP. Next, it is bound by Dicer, another ribonuclease, which 
cleaves the hairpin structure such that the ~21 nucleotide fragment can be complexed with 
Argonaut to form the RNA-induced silencing complex (RISC complex)37,38. Once the 
complex is formed, miRNAs can post-transcriptionally modify gene expression through a 
number of mechanisms. Based on the 4-9nt “seed sequence” of the miRNA complex, 
complementary base-pairing of target mRNA transcripts can occur. This may lead to 
cleavage of the target mRNA, poly-A-tail shortening, or blockage of the ribosome binding 
site, preventing translation etc. In vertebrates, miRNAs primarily function by degrading 
target mRNAs39. Currently, the specific role miRNAs play in MD is under-investigated. 
MiR-188 has been identified as a biomarker of Duchenne’s MD, but it is unclear if this 
miRNA might be contributing towards the phenotype40. Moreover, numerous miRNAs 
have been shown to modulate apoptosis, regeneration, cell growth and organization: 
processes that are likely pertinent to MD. Thus, investigating both miRNAs and lncRNAs 
is a necessary step towards a better understanding of the genetic pathways involved in this 
disease, and may have implications on the range of phenotypic severity and lifespan MD 
patients display. By incorporating protein-coding gene expression, miRNA expression, and 
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lncRNA expression in genetic regulatory pathways, treatments could emerge that target 
specific pathways to treat resulting symptoms, informing and advancing our understanding 
of MD.  
1.9 RNA sequencing to measure gene expression  
RNA sequencing (RNA-Seq) is a high-throughput method to determine gene 
expression. It can be used to identify differentially expressed genes, genes that are turned 
on or off in certain situations and in response to stimuli, which can be used to answer 
numerous research questions. RNA-Seq can also be used to examine alternative splicing 
where exon usage may vary in different tissues or samples.  
Illumina high-throughput RNA sequencing begins with isolation of RNA transcripts. Since 
total RNA recovered using standard procedures contains >80% ribosomal RNA (rRNA)41, 
standard protocol includes selection for poly-adenylated sequences using magnetic beads 
or cellulose coated with oligo-dT molecules, a process that removes most of the rRNA. 
Next, the transcripts are fragmented and converted to cDNA with ligated adapters used for 
next generation sequencing (NGS). To ensure proper removal of rRNAs, rRNA depletion 
is performed. Multiple strategies for rRNA depletion exist, but most utilize rRNA probes 
that target rRNA transcripts, signaling them for degradation. For example, Roche’s KAPA 
RNA HyperPrep Kit with Riboerase utilizes rRNA DNA probes that hybridize to rRNA 
fragments, forming RNA-DNA hybrids, that are targeted by RNase H for degradation. This 
method has less off-targets and preserves a higher proportion of non-coding RNAs than 
other strategies for rRNA depletion42. 
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Samples are then sequenced using Next Generation Sequencing (NGS). Following 
this, a workflow is performed that utilizes multiple software to assemble and align reads, 
annotate genes, and calculate gene expression. The output of sequencing is typically two 
FASTQ files for each sequenced sample, one for forward reads and another for reverse 
reads. First, these files are checked using FastQC43 which determines the read length and 
quality. Next, the two FASTQ files are concatenated into one file, trimmed of the adapters 
used for sequencing, and aligned to a given genome using either HISAT244 or BowTie45. 
If one is interested in identifying novel transcripts, Stringtie46 is run to align the transcripts 
to genes and identify ensembl-annotated genes. The bam file that is the result of BowTie 
or HISAT2 is run through HTSeq247 which counts the number of transcripts that align to 
each of the genes, and then DESeq248 can be used to identify differentially expressed genes.   
Small RNA sequencing allows for the preferential sequencing of microRNAs (miRNAs). 
It selects miRNAs using bead or gel-based size selection. Unlike most cellular RNAs, 
mature miRNAs possess both a 3’ hydroxyl and a 5’ phosphate which allows for 
preferential adapter ligation49. From there, cDNA preparation using reverse transcriptase, 
sequencing, and transcript alignment and annotation occur as would in traditional RNA 
Sequencing.  
RNA Sequencing provides information about the expression of protein coding 
genes which account for a mere 2% of the genome, as well as non-protein coding like long 
non-coding RNAs (lncRNAs) and microRNAs (miRNAs). A relatively newer view of the 
molecular mechanisms that lead to phenotype is that the way protein-coding gene are 
regulated, where they are expressed and when, is just as important as the protein-coding 
genes themselves. Therefore, traditional sequencing that excludes non-coding genes, 
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potent genetic regulators of protein-coding genes, excludes a plethora of valuable 
information. Non-coding regulatory genes are severely under investigated in MD, thus, we 
aimed to emphasize them in our analysis.  
1.10 MiRNA Network Attack 
Co-expression networks are used to understand large genetic networks. In the 
context of gene expression, they can be used to identify possible interactions between 
genes. In these networks, the nodes represent individual genes, and edges between them 
indicates that two genes are correlated – that their levels of expression are similar i.e. r2 
>0.75). These co-expression networks can then be used for further analyses to identify gene 
candidates. 
Network attack models are a computational method of modeling a network’s 
vulnerability in response to removal of nodes or edges. This is used for identification of 
the most important edges or nodes, those that contribute most towards the network 
stability50. They have been used to model social networks, identify key players in criminal 
organizations51, and model power grids52, and have proposed benefits in modelling 
relationships from large datasets generated from biological research50.  
Network stability is defined by multiple parameters including the characteristic 
path length, the degree of separation, and the network size.  The characteristic path length 
is the shortest path (the least number of edges) between two nodes. Nodes or edges that are 
most important to the network stability, cause relatively large changes in the characteristic 
path length upon removal. Another factor to consider in network attack graphs is the 
degrees of separation. The value of the degrees of separation defines the number of nearly 
independent networks, those with relatively few connections to other networks. An 
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example of this could be the social activities of people worldwide. If the nodes were people, 
and the edges were interactions, one would expect that each continent would have its own 
relatively independent network that would consist of far fewer edges connecting nodes 
between different continents than nodes within the same continent. Thus, the degree of 
separation would be six, based on the number of inhabited continents. Moreover, if you 
repeatedly selected edges that were transcontinental, after removing the last 
transcontinental edge, a huge change in the characteristic path length would occur. The 
network size is another useful parameter in finding important nodes. By repeatedly 
removing nodes, large jumps in network size can be used to pinpoint nodes that contribute 
to network stability.  
Network attack has been used to model miRNA networks to compare miRNA 
expression in different forms of cancer53.  In the context of miRNA expression, nodes 
represent individual miRNAs and edges connect the distinct miRNAs if they show similar 
patterns of expression between different timepoints, treatments, etc. These co-expression 
networks can identify miRNAs that are controlled by the same transcriptional pathway or 
functionally related54. Furthermore, by attacking the network through removal of miRNAs, 
nodes can be identified that cause large changes in characteristic path length or network 
size. These nodes are thus important in maintaining the structure of the network and are 
interesting candidates for further investigation. 
1.11 MiRNA gene target analysis  
MiRNAs recognize mRNA targets based on complementary base pairing of the 
seed sequence of the miRNA with the mRNA transcript. TargetScanFish55 (version 6.2) is 
a database with lists of zebrafish mRNAs targeted by zebrafish miRNAs that can be used 
 
16 
 
in combination with differential gene expression to predict miRNA/mRNA relationships. 
If a miRNA is differentially expressed and it is targeting a specific mRNA transcript, it 
would be expected that the mRNA transcript would be differentially expressed in an 
opposite direction of the miRNA, since most miRNAs cause degradation of their targets. 
The relationship between miRNAs and their mRNA targets can be used to identify 
upstream putative pathways that lead to biological differences. 
1.12 Research Objectives   
The primary goal of this research is to construct genetic regulatory networks that link 
miRNAs, lncRNAs, and protein-coding genes to cellular processes implicated in 
dystroglycanopathy phenotypes. We will do so with the following objectives: 
1. Identify previously annotated lncRNAs and miRNAs that are differentially 
expressed in the mutants.  
a. Predict miRNA targets  
2. Identify candidate novel lncRNAs via de-novo analysis from unannotated 
transcripts that are differentially expressed in the gmppb mutants. 
a. Characterize these lncRNAs and the adjacent genes to determine if they are 
relevant to MD.  
3. Incorporate lncRNA, miRNA, and protein-coding gene expression to construct a 
genetic regulatory network that may contribute towards our understanding of the 
molecular pathways involving MD phenotype.  
4. Characterize the different types of mutations that were induced in the gmppb 
mutants through Polymerase Chain Reaction (PCR) amplification of gmppb 
mutants and subsequent sequencing.   
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2. MATERIALS AND METHODS:   
2.1 Overview of the experimental design 
Four biological replicate samples of each treatment at each timepoint were 
submitted for rRNA depletion, followed by small RNA sequencing and mRNA sequencing 
(Figure 4). This included four samples of heterozygous gmppb mutants, four samples of 
homozygous gmppb mutants that displayed mild phenotypes, and four samples of 
homozygous gmppb mutants that displayed severe phenotypes. Each sample consisted of 
total RNA made from homogenizing three embryos (as described in section 2.2). The two 
timepoints included were 4 and 7 days post fertilization (dpf). For the small RNA 
Sequencing, only 3 samples were submitted for each treatment due to insufficient total 
RNA quantity.  
 
Figure 4. Experimental overview of RNA Sequencing and small RNA Sequencing in 
gmppb+/- controls and gmppb-/- mutants exhibiting mild or severe phenotypes.  
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2.2 RNA extraction 
Homozygous mutant and sibling control embryos were raised to the specified time 
point (4 or 7 days post fertilization), and then the mutants were classified based on 
birefringence using a confocal microscope in the Henry Lab. Birefringence was quantified 
using FIJI as previously described20. Mutants with a percent area and a percent Mean Gray 
Value at 85% or higher were classified as mild mutants; mutant embryos that did not meet 
this standard were classified as severe30. Zebrafish were segregated into separate tubes 
based on this classification system, euthanized via tricane, and preserved in 300 µL of trizol 
by the Henry Lab following an approved University of Maine IACUC protocol. To obtain 
sufficient RNA for RNA Sequencing, small RNA Sequencing, and quantitative Polymerase 
Chain Reaction (qPCR), each sample consisted of 3 zebrafish embryos.  
Samples were defrosted and homogenized using a Fisher PowerGen 125 (Fisher 
Scientific, Waltham, MA) mechanical homogenizer. RNA Extraction was performed using 
a Quick-RNA MicroPrep kit from Zymo following the manufactures protocol (Zymo 
Research, Irvine, CA). Samples were centrifuged at 12,000xg for 1 minute and the 
supernatant was removed and placed into a clean test tube. One volume ethanol (95-100%) 
was added to each sample, mixed well, and then the mixture was transferred to a Zymo-
Spin IC column with a collection tube. The column was centrifuged 30 seconds at 12,000xg 
and the flow through was discarded. The column was washed with 400 µL RNA Wash 
Buffer, centrifuged for 30 seconds at 12,000xg, and flow through was discarded. A DNase 
I Mastermix was prepared in an RNase free tube with 5 µL DNase I and 35 µL DNA 
Digestion buffer per sample. The master mix was mixed via gentle inversion. Next, the 
column was washed with 400 µL of RNA Prep Buffer followed by 700 µL RNA Wash 
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Buffer, each time centrifuging for 30 seconds at 14,000xg and discarding the supernatant. 
Next, the column was washed with 400 µL RNA Wash Buffer and centrifuged 2 minutes, 
then placed into a new RNase free tube. 10 µL of DNase/RNase Free Water was added to 
the center of the column and the sample was eluted via centrifugation for 30 seconds at 
14,000xg. The eluted RNA quality and concentration was immediately read by a Thermo 
Scientific NanoDrop OneC Spectrophotometer (Waltham, MA) and then samples were 
stored in a -80C freezer. The Zymo protocol is available online at https://files.zymo 
research.com/protocols/_r1050_r1051_quick-rna_microprep_kit.pdf. 
2.3 RNA sequencing and small RNA Sequencing  
Samples were submitted for RNA sequencing at QuickBiology in Pasadena, 
California. Total RNA samples were assayed for quality using an Agilent Bioanalyzer 2100 
(Agilent Technologies, San Francisco, CA) by QuickBiology.  
Libraries for RNA-seq were prepared with a KAPA Stranded RNA-Seq Kit with a 
RiboErase (KAPA Biosystems, Wilmington, MA) system. Final library quality and 
quantity were analyzed by Agilent Bioanalyzer 2100 (Agilent Technologies, San 
Francisco, CA) and Life Technologies Qubit 3.0 Fluorometer (Life Technologies, 
Carlsbad, CA), respectively. The RNA Sequencing was performed on a HiSeq 4000 
Illumina Sequencer (Illumina Inc, San Diego, CA) with 150 base paired end reads.  
The same total RNA samples were submitted for small RNA Sequencing. The 
library was prepared according to Qiagen QIAseq miRNA library kit (Qiagen Inc, 
Germantown, MD) using 100 ng total RNA as input. Final library quality and quantity was 
analyzed by Agilent Bioanalyzer 2100 and Life Technologies Qubit 3.0 Fluorometer. The 
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Small RNA Sequencing was performed on an Illumina NextSeq 500 (Illumina Inc, San 
Diego, CA) with 75 base paired end reads.  
 
2.4 RNA sequencing annotation workflow  
FastQC version 0.11.943 was used to verify the quality of the RNA Sequencing 
reads prior to further analyses. All analyses were performed using Galaxy 
(https://usegalaxy.org) and the histories of analyses be accessed through Galaxy upon 
request. 
Following FastQC diagnostic analyses, each of the FASTQ files were concatenated 
tail-to-head to produce a single set of Forward (R1) and Reverse (R2) FASTQ files per 
sample. FASTQ files were then trimmed using Trimmomatic version 0.38.056 which 
removes the sequencing adapters, and low quality bases. The forward and reverse reads 
were mapped to the GRCz11/danRer11 (May 2017) zebrafish genome assembly 
(https://www.ncbi.nlm. nih.gov/assembly/ GCA_000002035.4/) using HISAT2 version 
2.1.044. The resulting BAM (binary alignment and mapping) file for each sample was then 
used to develop gene models using StringTie version 3.1.6 and the GRCz11 Ensembl 
(version 98) GTF annotation file. The GTF file for each sample was combined using 
StringTie Merge to produce a single GTF annotation file. A FASTA formatted sequence 
file for each transcript in the GTF file was produced using GFFread from within Cufflinks 
version 2.1.1.257. Next, the BAM files were run through HTSeq version 0.9.147 to count 
the number of reads that map to exons of genes in the GTF annotation file.  Read counts 
per gene per sample were analyzed using DESeq2 version 2.11.40.648. Four different 
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pairwise sample group comparisons were made to determine which genes were 
differentially expressed. These comparisons included: 4dpf sibling vs. 4dpf mild, 4dpf 
sibling vs. 4dpf severe, 7dpf sibling vs. 7dpf mild, and 7dpf sibling vs. 7dpf severe. For 
each pairwise comparison, the normalized expression across all samples, log2 Fold Change 
(log2FC), log ratio statistic, p-value, and false-discovery rate (FDR) adjusted p-value were 
computed for each gene using DESeq2. After merging the DESeq2 files with the Ensembl 
annotation, genes were subset based on gene type (i.e protein-coding, long non-coding 
RNAs, miRNAs, etc.). Additionally, a script was run to annotate un-annotated transcripts 
that were structurally similar to other annotated transcripts. Finally, GffCompare was used 
to identify unannotated transcripts that were used for novel lncRNA identification.  
Below is a pictorial example of this workflow using triplicate wildtype and 
triplicate gmppb mutants (Figure 5). 
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2.5 Small RNA sequencing workflow 
Analysis of differentially expressed miRNAs was performed using miRExpress 
version 2.058 using only the read 1 (R1) FASTQ files for each of the three biological 
replicate samples profiled using small RNA sequencing. MiRExpress was used to trim 
adapters and then align the trimmed reads to precursor miRNA sequences provided by 
miRGeneDB version 2.059. The number of aligned reads to the 5p- or 3p-ends of the 
precursor miRNA sequences were reported. These read counts for the mature miRNAs 
were analyzed using DESeq2 to perform the same four pairwise comparisons done for the 
RNA sequence described above.  
2.5 Splicing analysis of gmppb mutants 
To verify incorporation of the STOP cassette in the gmppb homozygous mutants, 
gDNA hotshot extractions were performed based on the procedure described by Gagnon 
et. al29. One 4dpf embryo was placed in a PCR tube per sample in non-lethal tricane. Once 
the embryo appeared to be asleep, the liquid was removed and 20 µL of 50mM NaOH was 
added. The sample was heated in a PCR machine for 20-30 minutes at 95C and then cooled 
to 4C. 2 µL 1M TrisCl, Ph 8.0 was added and mixed via pipetting up and down. Samples 
were frozen at 4C prior to Polymerase Chain Reactions.  
To amplify the gmppb target region, PCR was performed with the reverse primer 
(TGAAAGCTCTGATTCTTGTCGGTG) and the forward primer (CTGGTGGAACTTG 
AGCATGTCGT). The genomic DNA was spun down on a bench top centrifuge and then 
2 µL was added to each reaction tube in a 96 well PCR plate. To the reaction each of the 
following were added: 1 µL of 20 uM primer (forward + reverse mixed), 0.125 µL Taq 
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Polymerase (5000 Units/mL, New England Biological Laboratory, Ipswich, MA), 0.5 µL 
of 10mM dNTPs, and 21.375 µL DI water -to bring the total volume to 25 µL. Samples 
were quickly mixed via inversion, spun down, and placed in the PCR machine with the 
following cycle temperatures and times: 
Step 1: 95 degrees 3 minutes initial denaturing 
Step 2: 95 degrees 20 seconds denature 
Step 3: 60 degrees 25 seconds anneal 
Step 4: 68 degrees 30 seconds extend 
Step 5: Repeat steps 2-4 34 more times 
Step 6: 68 for 5’ final extension 
Step 7: Hold samples at 4C  
 
The samples were submitted for sequencing at 10ng/mL and then the resulting 
forward and reverse reads were aligned with wildtype gmppb and the STOP cassette using 
Basic Local Alignment Search Tool (BLAST version 2.10.0)60. Mutants were categorized 
based on the types of mutations that were present and the degree of and location of stop 
cassette insertion. Mutated reads were analyzed using Open Reading Frame Finder (ORF 
Finder) to validate whether stop codons were present in all possible reading frames. Finally, 
the RNA Sequencing data was aligned based on the results and categorization of different 
mutations found via qPCR analysis, to attempt to categorize the mutants based on their 
gmppb mutations.
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2.6 Identification and characterization of differentially expressed novel and previously 
annotated lncRNAs and nearby genes 
Previously annotated differentially expressed lncRNAs were subset from the 
annotated genes as described previously in section 2.4. Unannotated transcripts were also 
subset as described in section 2.4.  Fasta Sequences for each of the transcripts were 
generated using GFFread57. To identify novel potential lncRNAs, the un-annotated 
sequences were run through Coding Potential Assessment Tool (CPAT version 1.2.2)61 and 
then RepeatMasker (version 4.1.0) to identify transcripts with high coding potential and 
highly repetitive transcripts, respectively. A perl script was used to subset transcripts with 
a coding potential less than 0.38. The RepeatMasker results were compiled to generate a 
ratio of repetitive bases per transcripts (Appendix B, Section B.2), and transcripts were 
subset based on a threshold of less than 50% repetitive bases.  
2.7 Characterization of differentially expressed protein coding genes 
Protein coding genes were subset from the annotated DESeq files generated in 
section 2.4. Differentially expressed genes are defined as those with either adjusted or non-
adjusted p-values less than 0.05. Information about each of the genes was gathered using 
Ensembl Biomart66, including the gene name and description. Venny 2.0 
(https://bioinfogp.cnb.csic.es/tools/venny/) was used to subset genes based on temporal 
and sample dependent expression. Enriched gene sets with Gene Ontology annotations 
were determined using David67,68 and Panther69. Additional functional information about 
genes was obtained from GeneCards64 and AmiGO70,71.   
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2.8 Characterization of differentially expressed miRNA and network attack  
Differentially expressed miRNAs were subset from the small RNA Sequencing 
data based on an adjusted p-value less than 0.05. An R script was generated to determine 
the predominantly expressed miRNA based on expression, thus, the non-predominantly 
expressed miRNA arm (otherwise known as the passenger strand) was discluded from 
future analyses (Appendix B, section B.1). Venny 2.0 was used to look for trends in 
expression across multiple samples and time points.  
Network attack plots were generated using a combination of R and python scripts 
to better understand the robustness of the networks present in the 4dpf/7dpf siblings, 
4dpf/7dpf mild mutants, and 4dpf/7dpf severe mutants. Scripts to generate these plots can 
be requested. Networks were imported into and visualized with Cytoscape version 3.7.272. 
 
2.9 miRNA target analysis 
MiRNA mRNA targets were identified from TargetScanFish55. The MirBase IDs 
present in the TargetScanFish files were converted to MirGeneDB59 IDs using 
MiRExpress58 which are the IDs present in the DESeq2 data. MiRNAs in the small RNA 
Sequencing dataset that were differentially expressed at 4dpf in the severe mutants were 
subset according to an adjusted P value < 0.05. Only the predominant strand of each 
miRNA was included in the analyses, the passenger strand was excluded from the data. 
Ensembl annotated genes from RNA sequencing that were differentially expressed at 4dpf 
in the severe gmppb mutants according to an unadjusted p value < 0.05 were also subset. 
These two lists were merged to look for differentially expressed miRNAs with 
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differentially expressed mRNA targets. Finally, since miRNAs typically induce 
degradation of their mRNA targets, miRNA and mRNA targets were subset based on an 
opposite pattern of differential gene expression (i.e. miRNA was downregulated, and 
mRNA was upregulated OR miRNA was upregulated, and mRNA was downregulated). 
This data was used to generate networks in Cytoscape version 3.7.272.  
2.10 Comparison of gene expression to cardiac regeneration 
To highlight genes that might be involved in muscle-related phenotypes, protein-
coding and miRNA gene expression was compared to that of a previous study exploring 
differentially expressed genes involved in cardiac regeneration in zebrafish73. Venny 2.0 
was used for comparison and gene ontologies for the protein-coding genes were determined 
as described in section 2.7.  
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3. RESULTS 
3.1 mRNA sequencing of gmppb mutants  
3.1.1 Identifying differentially expressed Ensembl annotated genes.  
To identify potential gene candidates involved in modulating phenotypic severity, 
differentially expressed gene transcripts were determined by comparing expression 
between pairs of sample groups (Figure 6). The gene transcripts analyzed were those 
annotated by Ensembl. As expected, using adjusted p-values, a more stringent significance 
threshold decreases the number of genes defined as differentially expressed. At both 
timepoints, severe mutants compared to sibling controls had a greater number of 
differentially expressed genes relative to the mild mutants compared to sibling controls. 
Next, a comparison of sets of differentially expressed genes from the four pairwise 
comparisons was performed to determine the temporal and sample-specific expression of 
the Ensembl annotated genes (Figure 7). 
 
Figure 6. From mRNA sequencing, a list of differentially expressed gene transcripts 
defined by a threshold of p<0.05, or adjusted p<0.05 were subset. Those with Ensembl 
annotations are included in this figure. The table shows the number of differentially 
expressed genes in each sample according to the threshold definition of differentially 
expressed. 
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Figure 7. Venn diagrams of differentially expressed Ensembl annotated genes. Panel A 
includes genes with unadjusted p-values < 0.05 while panel B includes genes with 
adjusted p-values < 0.05. Regions of overlap indicates genes that are differentially 
expressed at the multiple specified timepoints or phenotypes. Percentages are included to 
indicate the number of genes in each category over the total number of differentially 
expressed genes.  
 
Next, to characterize genes differentially expressed in the severe mutants at both 
4dpf and 7dpf, Gene Ontology annotations were performed using PANTHER and DAVID. 
Of the 82 differentially expressed genes (p-value < 0.05) common between 4dpf and 7dpf, 
but not shared with 4dpf or 7dpf mild, only 47 were mapped to genes represented in 
PANTHER or DAVID. Gene Ontology terms of interest included muscle organization, 
extracellular matrix, cell adhesion, mitochondrial function, the immune system, and 
transcriptional regulators (Tables 3 and 4).  
The ten most differentially expressed Ensembl annotated genes were subset as 
indicated by the largest positive or negative fold change (log2 FC) and an adjusted p-value 
< 0.05. Eight of these genes came from the 7dpf severe mutants and two came from the 
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4dpf severe mutants (Table 2). Three of these genes lack gene descriptions, and two of 
them were not annotated as protein-coding genes.  
It is important to note that in these analyses, all Ensembl genes, regardless of 
whether they were protein-coding or not, were included. Therefore, non-coding genes, 
including miRNA precursors and annotated lncRNAs, were present. Of the 881 total genes 
differentially expressed across all pairwise comparisons, 22 were annotated as lncRNAs 
and two as miRNA precursors. Of just the 82 genes differentially expressed in both the 
severe mutants, one was annotated as a lncRNA and there were no annotated miRNA 
precursors.  
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Table 3.  Differentially expressed (unadj p <0.05) genes with selected Gene Ontology 
annotations at 4 and 7dpf in the severe mutants.  
 
Gene ID Name Gene Description  4dpf Severe 7dpf Severe 
Muscle Organization Base  log2FC P Val Base log2FC P Val 
ENSDARG 
00000000563 
ttn.1 titin, tandem duplicate 
1 
52 0.83 0.039 46 -0.98 0.042 
ENSDARG 
00000028213 
ttn.2 titin, tandem duplicate 
2 
47 0.73 0.047 42 -0.92 0.030 
ENSDARG 
00000045302 
smpx small muscle protein X-
linked 
124 -0.70 0.001 131 -0.41 0.027 
Extracellular Matrix 
ENSDARG 
00000042816 
mmp9 matrix 
metallopeptidase 9 
43 1.00 0.001 36 -0.85 0.008 
ENSDARG 
00000061904 
fhod3b formin homology 2 
domain containing 3b 
24 -0.97 0.012 90 -2.56 0.000 
Cell Adhesion 
ENSDARG 
00000093008 
adgrf3b adhesion G protein-
coupled receptor F3b 
13 -1.36 0.005 30 -0.87 0.024 
Immune System 
ENSDARG 
00000042816 
mmp9 matrix 
metallopeptidase 9 
43 1.00 0.001 36 -0.85 0.008 
Mitochondrial Function 
ENSDARG 
00000038643 
alas2 aminolevulinate, delta-, 
synthase 2 
258 -1.62 0.001 733 -1.31 0.002 
ENSDARG 
00000063922 
mt-nd6 NADH dehydrogenase 
6, mitochondrial 
581 0.87 0.000 374 -0.55 0.041 
ENSDARG 
00000069852 
lipt2 lipoyl(octanoyl) 
transferase 2 
75 0.58 0.013 70 -0.64 0.006 
Developmental Pathways 
ENSDARG 
00000074148 
RAS 
rbpjl 
recombination signal 
binding protein for ig 
kappa J region 
1073 0.53 0.001 587 1.81 0.000 
ENSDARG 
00000040959 
NOTCH 
rabl3 
RAB, member of RAS 
oncogene family-like 3 
126 0.48 0.033 65 1.34 0.000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
Table 3 Continued 
Gene ID Name Gene Description  4dpf Severe 7dpf Severe 
Transcriptional Regulation Base  log2FC P Val Base log2FC P Val 
ENSDARG 
00000034300 
sema3c sema domain, 
immunoglobulin 
domain (Ig), 
(semaphorin) 3C 
93 -1.69 0.000 207 -0.87 0.000 
ENSDARG 
00000035187 
abl1 c-abl oncogene 1, non-
receptor tyrosine kinase 
111 0.39 0.042 102 -0.53 0.019 
ENSDARG 
00000036036 
mdka midkine a 83 -0.57 0.015 98 -0.45 0.045 
ENSDARG 
00000038859 
rgs20 regulator of G protein 
signaling 20 
191 -0.60 0.010 202 0.60 0.032 
ENSDARG 
00000040959 
rabl3 RAB, member of RAS 
oncogene family-like 3 
126 0.48 0.033 65 1.34 0.000 
ENSDARG 
00000053370 
eif3jb eukaryotic translation 
initiation factor 3, 
subunit Jb 
154 0.57 0.026 98 0.67 0.004 
ENSDARG 
00000055792 
foxo4 forkhead box O4 11 1.50 0.000 8 -0.89 0.047 
ENSDARG 
00000056079 
l3mbtl2 L3MBTL histone 
methyl-lysine binding 
protein 2 
38 0.99 0.001 16 1.17 0.002 
ENSDARG 
00000056590 
calca calcitonin/calcitonin-
related polypeptide, 
alpha 
31 -2.02 0.000 32 3.78 0.000 
ENSDARG 
00000071727 
si:dkey-
37o8.1 
si:dkey-37o8.1 196 -0.53 0.003 230 -0.34 0.041 
ENSDARG 
00000074148 
rbpjl recombination signal 
binding protein for ig 
kappa J region 
1073 0.53 0.001 587 1.81 0.000 
ENSDARG 
00000075670 
rereb arginine-glutamic acid 
dipeptide (RE) repeats 
b 
34 0.93 0.005 36 -1.26 0.000 
ENSDARG 
00000095332 
si:dkey-
14d8.1 
si:dkey-14d8.1 28 0.81 0.023 22 -0.95 0.010 
ENSDARG 
00000100536 
nkrf NFKB repressing 
factor 
109 0.57 0.029 83 0.46 0.029 
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Table 4.  Differentially expressed (adjusted p <0.05) genes with selected Gene Ontology 
annotations at 4 and 7dpf in the severe mutants. 
Gene ID Name Gene 
Description  
4dpf Severe 7dpf Severe  
 Base  log2FC Adj P Base log2FC Adj P 
ENSDARG 
00000005941  
clul1 clusterin-like 1 
(retinal) 
30 -2.13 0.000 121 0.25 0.000 
ENSDARG 
00000074148 
RAS 
rbpjl  
recombination signal 
binding protein for ig 
kappa J region-like  
107
3 
0.53 0.020 587 0.23 0.000 
ENSDARG 
00000038643 
alas2 
 
aminolevulinate, 
delta-, synthase 2  
258 -1.62 0.028 733 0.41 0.020 
ENSDARG 
00000034300 
sema3c  sema domain, Ig, 
secreted, semaphorin 
3C  
93 -1.69 0.000 207 0.25 0.008 
ENSDARG 
00000056079 
l3mbtl2 
 
L3MBTL histone 
methyl-lysine 
binding protein 2  
38 0.99 0.018 16 0.38 0.026 
ENSDARG 
00000056590 
calca 
 
calcitonin/calcitonin-
related polypeptide, 
alpha  
31 -2.02 0.000 32 0.48 0.000 
ENSDARG 
00000074148 
rbpjl 
 
recombination signal 
binding protein for ig 
kappa J region-like  
107
3 
0.53 0.020 587 0.23 0.000 
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3.1.2 Identifying novel transcripts for lncRNA analysis. 
The ensembl annotated gene transcripts represented only a fraction of the total 
differentially expressed genes in the gmppb mutants. It is likely that within this subset of 
differentially expressed genes, previously unidentified lncRNAs exist. To identify 
potential lncRNAs, a previously described workflow was used to subset novel transcripts 
with low coding potential and low repetitiveness (Figure 8).   
 
 
Figure 8. Identification of potential lncRNAs. A. Total genes (blue = ensembl annotated, 
yellow = unannotated) with adjusted p-values less than 0.05 in 4dpf severe mutants. B. 
Genes from panel A with Log2FC > 1 or < -1. C. Novel genes from panel B with Coding 
Potential < 0.38 as determined by CPAT. D. Novel Genes from panel C with < 50% 
repetitive bases.  
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3.2 Small RNA sequencing of gmppb mutants to identify differentially expressed 
miRNAs 
Since standard mRNA sequencing selects for poly-adenylated transcripts, and 
processed miRNA transcripts are not poly-adenylated, small RNA sequencing was 
performed to measure processed miRNA expression74. In the dataset, there were a total of 
265 miRNAs expressed across all samples. Figure 9 shows the number of differentially 
expressed miRNAs in each sample; Figure 10 shows the overlap in differentially 
expressed miRNAs between samples.   
 
 
Figure 9. Number of differentially expressed miRNA as indicated by adjusted p-value < 
0.05 and unadjusted p-values < 0.05.  
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Figure 10. Overlap of differentially expressed miRNAs. A: miRNAs that are differentially 
expressed according to an unadjusted p-value < 0.05. B: miRNAs that are differentially 
expressed according to an adjusted p-value < 0.05. Venn diagrams made with Venny 2.0. 
3.3 MiRNA co-expression networks  
Co-expression networks can be used to identify sets of miRNAs that have 
correlated expression patterns that can be used to infer common function. The topology 
of these networks can be analyzed to determine nodes and edges that contribute towards 
network stability. Number of miRNA nodes in each of the three co-expression networks 
is listed in Table 5. Both characteristic path length and resultant network size are two 
parameters used to identify important nodes (Figures M1 and M2). MiRNAs that, upon 
removal, cause relatively large changes in characteristic path length are listed in Table 6.  
 
Table 5. Number of nodes in miRNA co-expression networks. 
Sample: Number of Nodes 
Sibling 4dpf and 7dpf  221 
Mild 4dpf and 7dpf  255 
Severe 4dpf and 7dpf  264 
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Figure 11. Characteristic path length upon removal of individual nodes in miRNA 
expression.  miRNAs in each plot that upon removal cause relatively large changes in path 
length are labeled. Resultant characteristic path length upon removal of miRNA nodes in 
sibling 4dpf and 7dpf co-expression network (A), mild 4dpf and 7dpf co-expression 
network (B), and severe 4dpf and 7dpf co-expression network (C). D has all three 
networks overlaid into one graph.  
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Table 6. miRNAs that upon removal cause gaps in characteristic path length 
4dpf 7 dpf Sibling 4dpf 7dpf Mild 4dpf 7dpf Severe 
Dre-Mir-204-P2a-5p Dre-Mir_103-P3b-3p Dre-Mir-17-P2a1-5p 
Dre-Mir-15-P2a2-5p Dre-Mir-126-P1-3p Dre-Mir-132-P1a-3p 
Dre-Mir-132-p2a-5p  Dre-Mir-130-P3b1-3p 
  Dre-Mir-103-P3a-3p 
  Dre-Let-7-P1b-5 
 
 
 
Figure 12. Network size upon removal of nodes from sibling (black), mild (blue), and 
severe (red) 4dpf and 7dpf co-expression networks.  
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3.4 miRNA target prediction at 4dpf in the gmppb severe mutants 
TargetScanFish was used to predict mRNA targets of miRNAs, and analyses were 
performed to identify miRNA and mRNA targets with opposite expression at 4dpf in the 
severe mutants. Only the predominantly expressed miRNAs were included in this 
analysis. The first network with miRNAs upregulated and Ensembl annotated genes 
consists of a total of 8 upregulated miRNAs and 13 downregulated Ensembl genes, for a 
total of 37 interactions (Figure 13, Panel A). The second network has 7 downregulated 
miRNAs and 9 upregulated Ensembl genes for a total of 18 interactions (Figure 14, Panel 
B). Expression of each of the targeted genes is included in Tables 7 and 8. 
 
 
 
41 
 
 
Figure 13. MiRNA and mRNA target interactions at 4dpf in gmppb severe mutants. A: 
Each of the green nodes is an upregulated miRNA (unadjusted p <0.05); each of the red 
nodes are downregulated ensembl annotated genes (adjusted p < 0.05). B: Green nodes 
are upregulated ensembl annotated genes, red nodes are downregulated miRNAs. Edges 
are denoted by arrows and show miRNAs targeting mRNAs based on TargetScanFish 
data. The width of the edges is based on the context score of the interaction between the 
miRNA and mRNA.  
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Table 7. Upregulated mRNA targets of downregulated miRNAs in 4dpf Severe mutants.  
Gene ID Name Gene Description  4dpf Severe  
 Base  log2FC Adj P 
ENSDARG0
0000011533 
sema6dl Sema, transmembrane, 
cytoplasmic domain 
semaphorin 6D like  
124 4.99 5.3E-41 
ENSDARG0
0000044135 
cenpp centromere protein P 134 0.56 4.0E-02 
ENSDARG0
0000053062 
CR628323.2 gap junction epsilon-1 
protein-like 
84 0.73 2.0E-02 
ENSDARG0
0000055792 
foxo4 forkhead box O4 11 1.50 8.3E-03 
ENSDARG0
0000057121 
c7b complement component 
7b 
23 1.63 9.6E-03 
ENSDARG0
0000062319 
si:dkey-
103g5.3 
si:dkey-103g5.3 56 2.12 8.2E-08 
ENSDARG0
0000073711 
mmrn2b multimerin 2b 261 0.82 4.8E-04 
ENSDARG0
0000076135 
mmrn2a multimerin 2a 54 0.78 3.0E-02 
ENSDARG0
0000078059 
nudcd2 NudC domain containing 
2 
207 1.53 3.9E-10 
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Table 8. Downregulated mRNA targets of upregulated miRNAs in 4dpf Severe mutants. 
Gene ID Name Gene Description  4dpf Severe  
 Base  log2FC Adj P 
ENSDARG0
0000000183 
ptpn4b protein tyrosine phosphatase 
non-receptor type 4b 
461 -1.49 4.5E-07 
ENSDARG0
0000005941 
clul1 clusterin-like 1 (retinal) 30 -2.13 3.0E-04 
ENSDARG0
0000012030 
dnaaf1 dynein, axonemal, assembly 
factor 1 
18 -1.21 1.3E-02 
ENSDARG0
0000034300 
sema3c Sema and ig domain, 
secreted, (semaphorin) 3C  
93 -1.69 2.2E-05 
ENSDARG0
0000038643 
alas2 aminolevulinate, delta-, 
synthase 2 
258 -1.62 2.8E-02 
ENSDARG0
0000039422 
fuom fucose mutarotase 30 -1.15 2.0E-02 
ENSDARG0
0000045302 
smpx small muscle protein X-
linked 
124 -0.70 3.1E-02 
ENSDARG0
0000056590 
calca calcitonin/calcitonin-related 
polypeptide, alpha 
31 -2.02 3.1E-05 
ENSDARG0
0000070432 
ino80 INO80 complex ATPase 
subunit 
459 -1.01 1.2E-02 
ENSDARG0
0000070730 
gabra5 gamma-aminobutyric acid 
(GABA) A receptor, alpha 5 
41 -0.93 1.6E-02 
ENSDARG0
0000079013 
dpy19l
3 
dpy-19 like C-
mannosyltransferase 3 
313 -0.99 2.2E-05 
ENSDARG0
0000079366 
ppp1r9
ba 
protein phosphatase 1, 
regulatory subunit 9Ba 
135 -0.71 5.9E-03 
ENSDARG0
0000079946 
sqlea squalene epoxidase a 386 -0.71 9.2E-03 
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3.5 Splicing analysis of gmppb severe mutants  
To produce a truncated gmppb protein product, a stop cassette was designed by 
the Henry lab for incorporation into the early 5’ end of gmppb. The stop cassette had a 
total length of 75 nucleotides with homology domains on either end, each 20 nucleotides 
long; thus, the stop codons were from position 20-55. The left homology region was 
homologous to intron 2 of gmppb and the right homology region was homologous to the 
end of intron 2 and the beginning of exon 3 (Figure 14). 
 
  
Figure 14. Stop cassette structure. The stop cassette consists of a left gmppb homology 
domain and a right gmppb homology domain, with the stop codon region containing stop 
codons in every reading frame. Shown in light blue is the where the regions of homology 
share sequence with gmppb.   
 
To verify incorporation of the stop cassette into the gmppb mutants, PCR and 
sequencing of the gene gmppb was performed in 18 severe mutants. The mutants were 
categorized based on the sequencing results. Two categories of mutations were found, 
with one outlier. The first mutation, henceforth named the “partial double insertion”, was 
present in 3 of the mutants. It consisted of insertion of one full stop region and one partial 
stop region. In between the two stop cassettes was a right homology domain, and the left 
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homology region was truncated, with only 6 of the 20 original nucleotides (Figure 15). 
Notably, incorporation of this type of mutation resulted in a stop codon in every frame 
which would be expected to yield a truncated gmppb protein product75. 
 
Figure 15. Partial double insertion mutation structure. A. In three of the 18 sequenced 
mutants, the stop cassette insertion consisted of incorporation of a partial stop cassette 
followed by a full stop cassette. B. Shown is a simple pictorial representation of the 
mutation with a subset of the left homology, a full stop cassette, a portion of the right 
homology, a partial stop cassette, and then the right homology region.  
 
A second category of mutations was characterized by a “TG Gap” and was present 
in 14 of the 18 sequenced severe mutants (Figure 16). It was characterized by not only a 
lack of stop cassette insertion, but a truncated left homology region where 8 nucleotides 
were missing resulting in a truncated intron. ExpRESy indicated that stop codons were 
present in five of the six possible reading frames.  
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Figure 16. “TG Gap” mutation consists of an 8 base pair deletion between the left and 
right homology domains of gmppb. 
  
The findings from these analyses were next incorporated retroactively into the 
previously collected RNA Sequencing data by searching for specific subsequences of 
characteristic mutant regions in the FASTQ files. The queries “TAGTCTTACCTT” and 
“AAGGTAACACTA” were used to identify reads that represented the double stop 
cassette insertion mutation type in each of the samples (Figure QT) for both the forward 
and reverse reads. To verify that these were from the correct region of the genome (i.e. to 
confirm the were reads from gmppb), a secondary search was performed to determine the 
subset of these reads that contained six nucleotides of exonic gmppb that based on a read 
length of ~150nts should be present adjacent to the stop cassette (GGAGGC (e2) and 
GTCCGT (e3)) To find reads that represented the “TG Gap”, the subsequences 
“TGAACACCATTGGA” and “ACTTGTGGTAACCT” were searched for. In a similar 
fashion as previously described, the reads were subsequently searched for sequences from 
exon 2 and 3 of gmppb to verify that the reads were from the correct region (Figure 17).  
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Figure 17. Characterization of reads from RNA Sequencing. The number of reads were 
expressed as counts per million (CPM). A: Results from searching for 
“TAGTGTTACCTT” and “AAGGTAACACTA”, sequences representing four 
nucleotides of the right homology of the stop cassette (SC) and 4nts of the stop codons of 
the SC to either end. B: Results from searching for an additional sequence in the resulting 
reads from A, “GGAGGC” a sequence present in exon 2 of gmppb and “GTCCGT”, a 
sequence present in exon 3 of gmppb. This step ensures that the reads come from gmppb.  
C: In a similar fashion to graph A, a sequence, this time representing the TG Gap mutation 
identified from the PCR of gmppb mutants, was searched for. D: Number reads with exons 
2 and 3 subsequences.
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4. DISCUSSION & FUTURE DIRECTIONS 
4.1 mRNA Sequencing of gmppb mutants  
4.1.1 Differences in number of differentially expressed genes confirms differences in 
gmppb mild and severe mutants.  
Differentially expressed genes in the mild and severe mutants were identified using 
adjusted and non-adjusted p-values to identify genes that contributed to phenotypic 
severity. The shear difference in the number of differentially expressed genes correlates 
with the Henry’s Lab method of distinguishing between the mild and severe mutants 
(Figure 6). According to the unadjusted p-values, there are ~6 times more differentially 
expressed genes in the severe mutants as opposed to the mild mutants at 7dpf; according 
to the adjusted p-value, there are over 100 times more differentially expressed genes. 
Another interesting trend is that there are ~6 times more differentially expressed genes in 
the severe mutants at 7dpf as compared to the severe mutants at 4dpf. This could be due to 
compounding effects from irregulated pathways at early time points, leading to cellular 
responses aiming to restore the mutants to “normal” or “healthy” conditions. For example, 
multiple pathways must be activated to restore the tissue damage, and likely many of these 
are immune mediators. To better understand the gene pathways that contributed towards 
the severe phenotype, genes differentially expressed in the severe 4dpf and 7dpf mutants, 
but not the mild 4dpf and 7dpf mutants, were identified and further characterized.  
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4.1.2 Gene Ontology characterization reveals phenotype-relevant genes.  
Gene Ontology annotations for the genes differentially expressed in only the 4dpf 
and 7dpf severe mutants were determined using PANTHER and DAVID. These databases 
use manually curated and electronic annotations of Gene Ontology terms to characterize 
genes from the zebrafish model organism database, ZFIN. When examining functional 
annotation of genes, it is important to recognize that the zebrafish research community is 
smaller than the mouse and human research communities and the number of annotations 
are thereby smaller. Our entry list of 82 zebrafish genes resulted in a list of 47 genes with 
annotations. PANTHER and DAVID list Gene Ontology annotations for the genes that 
provide information about the biological processes, molecular function and cellular 
components associated with the protein products of the genes. Because of the relatively 
small number of input genes (82 for unadjusted p-values and 13 for adjusted p-values), the 
only term that was enriched was “nucleus” with a p-value of 0.005.  A list of MD relevant 
terms that appeared in the PANTHER and DAVID annotations was selected and genes 
were highlighted for further characterized based on these annotations. Terms included 
muscle organization, extracellular matrix associated, cellular adhesion, immune function, 
mitochondrial function, transcriptional regulators, and development pathways.  
The immune response to skeletal muscle disorganization and destruction is an 
important component of Muscular Dystrophy. Typically, following necrosis, the cellular 
debris is removed by macrophages and muscle satellite cells (MuSCs) migrate to the site 
of injury and proliferate to replace the lost tissue and restore muscle function. However, in 
most forms of MD, the MuSCs are unable to properly restore muscle function, and instead 
fibrotic tissue is deposited. The molecular mechanisms that modulate the immune response 
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are best characterized in Duchenne’s Muscular Dystrophy (DMD)76. In DMD, dystrophic 
muscle is invaded by CD4+ and CD8+ T cells, macrophages, eosinophils, and natural killer 
cells77,78. Depletion of myeloid and lymphoid populations decreases myonecrosis 79–81; 
depletion of B and T cells reduced fibrosis and TGF-β1(15), and ablation of inflammatory 
signals like IFNγ reduced the severity of muscle pathology82. Immunosuppressive 
medications, like the glucocorticoid prednisone, has also been shown to improve muscle 
strength in DMD patients and decrease myofiber injury83. However, the immune response 
in MD is not strictly deleterious. For example, M2 macrophages are induced by Il-4 and 
IL-13 to inhibit damaging inflammation and M1 macrophage mediated cytotoxicity84. 
Thus, the immune response is an important and delicate component of the pathology of 
MD and its role in dystroglycanopathy warrants further research.  
Multiple immune relevant genes were differentially expressed in the severe 
mutants. Of the 81 genes differentially expressed in both the 4dpf and 7dpf severe and not 
the mild mutants, only one was related to the immune system: matrix metalloproteinase-9 
(mmp9). MMPs have been shown to play an important role in myofiber functionality and 
skeletal muscle cell migration, differentiation, and regeneration. One way they do so is by 
degrading the extracellular matrix to allow for MuSC migration and differentiation to 
replace lost tissue. Inhibition of MMPs suppresses migration of MuSCs to the site of injury 
and impedes regeneration85,86. MMP-9 upregulation has been shown as a clinical biomarker 
for Duchenne’s Muscular dystrophy87. In the severe mutants, at 4dpf, mmp9 was 
upregulated, suggesting that the mutants were responding to the muscle damage by 
promoting satellite cell migration and differentiation, but at 7dpf, it was downregulated, 
suggesting a lack of response to damage (Table 3).  
 
51 
 
Another interesting candidate that was differentially expressed in the 4dpf and 7dpf 
with an adjusted p-value < 0.05 was clusterin-like-1 (clul1). The clusterin protein is a 
molecular chaperone that inhibits apoptosis through stabilization of the Ku70-Bax protein 
complex88. In the 4dpf severe mutants, clul1 was significantly downregulated, 
corresponding to an increase in apoptosis according to the aforementioned pathway (Table 
4). This could be a possible mechanism that results in myocyte death. However, apoptosis 
is often a response, a last resort to other cellular damage – thus, we suggest that this is a 
downstream effect of cellular damage in the MD mutants.  
Genes were also ranked based on the ratio of expression as indicated by the fold 
change (Log2 FC). The top 10 largest fold changes in expression were all in the severe 
mutants, eight of these were from the 7dpf severe mutants and two were from the 4dpf 
severe mutants. This is roughly the proportion we would expect based on the genes in each 
category that were differentially expressed according to the adjusted p-value (67 genes in 
the 4dpf severe and 338 genes in the 7dpf severe). Of the 10 most differentially expressed 
genes, functions were related to cell growth, nervous system development, and muscle 
contraction and relaxation.  
Antomacin 9a (ano9a) is part of the antomacin family which encodes calcium-
chloride channels and it was differentially expressed in the 7dpf severe gmppb mutants. 
There is little research characterizing ano9, however another member of this family is 
implicated in MD. Antomacin 5 (ANO5) mutations are one of the causes of Limb-Girdle 
MD. The protein product of this gene encodes a calcium-activated chloride channel that is 
most abundant in the endoplasmic reticulum (ER) of skeletal muscle89. It is predicted to be 
involved in regulating muscle contraction and relaxation. ANO5 also maintains calcium 
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homeostasis which promotes plasma membrane repair in damaged myofibrils.  Upon 
deletion of ANO5 or pharmacological inhibition of injury-triggered calcium flow form the 
ER to the cytoplasm, enabled injured patient myocytes to repair90. Although the specific 
role of ano9 is unknown, based on the role of ANO5, it is an interesting candidate for future 
research.  
Cell division cycle 23 (cdc23) was upregulated in the 7dpf severe mutants. Cdc23 
is a mitotic regulator that allows for cell cycle progression through the anaphase promoting 
complex (APC). We predict that the upregulation of this gene is likely related to an 
upregulation in cell division in an attempt to replace the lost myocytes. Interestingly, cdc23 
was the only cell division cycle gene that was upregulated in the 4dpf or 7dpf mutants.  
Finally, the sema family proteins were differentially expressed. Sema6dl was one of the 
genes with the largest fold change. It was upregulated with a Log2FC of nearly 5.0. Sema3 
was downregulated in both the 4 and 7dpf severe mutants. The sema receptors have been 
implicated in multiple signaling pathways with roles in regulating innervation. 
Specifically, sema3 has been shown to be involved in the innervation of skeletal muscle in 
the diaphragm91 and sema2 loss-of-function mutants have ectopic innervation in the 
muscle92. The loss of motor control in MD may be related to a lack of reinnervation or 
improper reinnervation after myocyte damage. In MD in general, the Neuronal Muscular 
Junctions (NMJ), the peripheral synapses that induce muscle contraction, are disorganized 
– a phenotype shared in the gmppb mutants. 
  Interestingly, two of the most differentially expressed genes were not protein 
coding – one was an antisense transcript and the other was a processed transcript, in the 
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future we would like to look at these genes in more detail, as they could be unannotated 
lncRNAs.  
Of course, there are many different lenses to view the gene expression data and 
identify candidates for future research. Another approach would be looking at genes that 
are differentially expressed in both the mild and severe mutants - but have a higher 
proportional change in expression in the severe as compared to the mild as indicated by the 
Log2 FC.  
Of the 881 annotated differentially expressed ensembl genes, 22 were annotated as 
lncRNAs and two as miRNA precursors. In the past, we have found that the Ensembl 
annotated lncRNAs tend to be highly repetitive – often exceeding 80% repetitive bases. 
Thus, we would like to analyze these lncRNAs further and search for any functional 
annotations in the literature in the future.  
4.1.4 Identifying novel transcripts for lncRNA analysis. 
To identify potential lncRNAs, novel transcripts were identified with low coding 
potential and less than 50% of repetitive bases according to a previously described lncRNA 
annotation workflow93. One thing that stands out in the 4dpf severe gmppb mutants is the 
high proportion of differentially expressed unannotated, novel genes as compared to the 
differentially expressed ensembl-annotated genes. In the past, this might have been 
considered “transcriptional noise”94, but difficulty still persists in identifying transcripts 
that are most likely to be related to the phenotype – and doing so requires extensive manual 
analysis. To characterize these 98 potential lncRNAs, ORFFinder will be used to look for 
open reading frames and BLAST will be used to identify transcripts with alignment to 
known protein coding genes. Furthermore, these transcripts will be aligned to novel 
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lncRNAs that were differentially expressed in caudal and cardiac regeneration in the 
zebrafish to look for commonly differentially expressed transcripts. Additionally, the genes 
to either side of the potential lncRNAs will be determined to indicate possible regulatory 
targets since some lncRNAs act in a “cis” mechanism. Homologous lncRNAs in humans 
will be identified. These analyses will be combined to generate a list of lncRNAs for qPCR 
validation.  
4.2 Small RNA sequencing of gmppb mutants to identify differentially  
expressed miRNAs 
To identify differentially expressed miRNAs, regulators of mRNA degradation, 
small RNA Sequencing was performed. The number of differentially expressed miRNAs 
according to an unadjusted p-value < 0.05 is similar in the 4dpf mild (55) and severe 
mutants (63) (Figure 9). However, when you consider the differentially expressed miRNAs 
according to the adjusted p-value, there were no differentially expressed miRNAs in the 
mild mutants. We suspect that there were not any miRNAs with an adjusted p-value < 0.05 
because we had only three biological replicates per sample group. Additional biological 
replicates would need to be characterized in a future experiment to more accurately 
characterize the biological variation in these sample groups. Since we only have three 
biological replicates, an unadjusted p-value can be investigated further to reveal differences 
in the phenotypic differences in the mild and severe mutants. In the analysis of the miRNAs 
using unadjusted p-values, another trend was a lower number of differentially expressed 
miRNAs in the 7dpf samples than in the 4dpf samples. This is contrasting to the trend 
observed in the Ensembl annotated genes where there were more differentially expressed 
genes in the 7dpf samples than in the 4dpf samples. Again, we suspect that this is a result 
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of only 3 biological replicates characterized by small RNA Sequencing compared to 4 
biological replicates for standard RNA sequencing.  
4.3 MiRNA co-expression networks reveal miRNAs that contribute towards network 
structural integrity.  
Three gene co-expression networks were produced using 4dpf and 7dpf siblings, 
4dpf and 7dpf mild gmppb mutants, and 4dpf and 7dpf severe gmppb mutants. Because we 
filtered out lowly expressed miRNAs, the number of co-expressed miRNAs (nodes) in each 
network was different. The number of nodes was lowest in the sibling network, 
intermediate in the mild network, and highest in the severe network (Table 5). The sibling 
showed the longest overall characteristic path length, the severe showed an intermediate 
characteristic path length, and the mild displayed the shortest characteristic path length 
(Figure M1). Network node attack analysis revealed multiple miRNAs that resulted in large 
changes in the characteristic path length after they were removed from the network (Table 
6). These miRNAs are candidates for further investigation. A shorter characteristic path 
length implies biological networks working in conjunction and synergy74. Perhaps, the 
additional stressor (the gmppb mutation), causes coordinated changes in miRNA 
expression in an attempt to combat the dysregulated pathways and processes. It is possible 
that the severe gmppb mutants have an intermediate characteristic path length because of 
an inability to respond as effectively to the physiological changes induced by the gmppb 
mutation.  However, using this type of analysis in gene networks is a novel, thus, we need 
to perform further research to determine how changes in network topology correlate with 
genetic function.  
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4.4 MiRNA target prediction at 4dpf in the gmppb severe mutants reveals an overlapping 
network of miRNAs regulating a cohort of Ensembl annotated genes  
By determining differentially expressed miRNAs with differentially expressed 
Ensembl annotated mRNA targets with opposite expression, miRNA/mRNA interactions 
can be predicted. In the 4dpf samples, a total of 55 such interactions were identified. The 
gene targets of these interactions were further characterized in relation to functions and 
processes implicated in the pathological progression of MD. 
Four of the mRNA targets were previously identified based on the 10 most 
differentially expressed analysis (calca) and differential expression (adj-p < 0.05) in the 
severe mutants at 4dpf and 7dpf (clu1 (yes1), alas2, and sema3c). This analysis therefore 
identified potential upstream regulators of potentially MD-relevant genes and pathways.  
To identify mRNA/miRNA interactions of interest, Gene Ontology annotations of 
the targeted mRNAs were analyzed, and a literature search was performed to identify 
mRNAs with MD-relevant function. From this analysis, 8 genes of interest were identified 
with functions related to cell growth regulation, immune activation, and neuron 
transmission and function.  
Cenpp and foxo4 are modulators of cell growth. Cenpp is a subunit of the CENPI-
associated centromeric complex and is required for kinetochore function and miotic 
progression96. In the severe 4dpf mutants, cenpp was upregulated - suggesting an increase 
in cell division – likely in an attempt to replace the damaged tissue. Multiple downregulated 
miRNAs are predicted to target cenpp, including dre-mir-31, dre-mir-155, and dre-mir-
34c. Forkhead box O transcription factors (foxo) are involved in cellular proliferation, 
stress resistance, and apoptosis97. Overexpression of FOXO3 is linked to skeletal muscle 
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atrophy through induction of atorign-1, a ubiquitin ligase98. Foxo4 is not well 
characterized, but based on its inclusion in the foxo family, it could play a similar role in 
inducing musclar atrophy. FOXO3 was significantly downregulated in the 4dpf severe 
mutants – suggesting an increase in muscle atrophy. This gene was predicted to be targeted 
by dre-mir-146a.  
The protein complement 7b (c7b) is a component of the complement pathway of 
the innate immune response that recruits the MAC attack complex to induce apoptosis of 
target cells. C7b was upregulated, suggesting an increase in the innate immune response in 
4dpf severe mutants that might contribute towards the loss of muscle mass in the mutants. 
C7b was predicted to be targeted by dre-mir-205 and dre-mir-155.  
The genes Protein Tyrosine Phosphatase Non-Receptor Type 4 (ptpn4b), Gamma-
Aminobutyric Acid Type A Receptor Subunit Alpha5 (gabra5), and Protein phosphatase 
1, regulatory subunit 9Ba (ppp1r9ba) are involved in neuronal function and protection. In 
the gmppb mutants, the neural muscular junctions (NMJs) are improperly formed and are 
likely related to loss of motor control in the mutant zebrafish (Figure 3). Ptpn4b has been 
shown to be involved in neural circuit formation in the brain of drosophila as it aids in 
establishing and stabilizing axonal projection patterns99. Thus, ptpn4 inhibition causes an 
increase in neuronal apoptosis100. In the 4dpf gmppb severe mutants at 4dpf severe, ptpn4b 
was downregulated – suggesting a decrease in this process. Gabra5 encodes a subunit of 
the GABA receptor, which is a ligand-gated chloride channel found in the brain. This 
receptor’s ligand is GABA, an inhibitory neurotransmitter. Another symptom related to 
MD is epilepsy which occurs in an estimated 6-7% of MD pediatric patients, as compared 
to 0.5-1% in the general population101,102. Thus, this gene’s decreased expression in the 
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4dpf severe mutants could be related to the loss of motor control inhibition in MD patients. 
Ppp1r9b is a factor involved in promoting the formation of filopodia outgrows that can be 
further remodeled to form dendritic spines that allow for excitation of neurons in the 
brain103. Ppp1r9b was downregulated in the mutants, suggesting a decrease in formation 
of filopodia outgrowths and a decrease in neural development and function.  Ptpn4b, 
gabra5, and ppp1r9ba were each predicted to be targeted by dre-mir-734. Ptpn4b and 
gabra5 were predicted to be targeted by dre-mir-212, dre-mir-135, and dre-mir-489; 
Ptpn4b was additionally predicted to be targeted by dre-mir-2187 and dre-mir-192.  
Overall, this analysis was able to identify upstream regulators of protein-coding 
genes with functions that appear to be related to the pathology of MD. To understand the 
role of miRNAs in targeting mRNAs more thoroughly, these same interactions should be 
identified in the other samples: 7dpf severe mutants, 4dpf mild mutants, and 7dpf mutants, 
and the results should be compared.    
4.5 Splicing analysis: gmppb severe mutants are characterized by two categories of 
mutations  
The splicing analysis revealed multiple types of mutations present in the severe 
mutants, emphasizing the need to untangle how this might contribute towards the 
phenotype severity. Interestingly, both types of mutations apparently resulted in the same 
general phenotype, since all eighteen of the sequenced fish has severe phenotypes. This is 
perhaps based on the observation that even with the “TG” gap mutation type, a substantial 
deletion and frameshift mutation is induced that results in stop codons in five of the six 
reading frames. However, for this to have any major impact on the length of the resultant 
protein, the intronic region must be translated since the mutation occurs in the 3’ region of 
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the intron. Perhaps, the mutation is disrupting the normal splicing of the mRNA which 
leads to inclusion of the intron either resulting in a truncated protein via the included stop 
codon or a dysfunctional protein based on the inclusion of the intron. Spliceosomes are 
small nuclear ribonucleoproteins that carry out splicing. The vast majority of eukaryotic 
introns are U2-type introns which are marked by a “GT” at the 5’ end and a “AG” at the 3’ 
end104. However, since the STOP cassette sequence contains multiple “GT” and “AT” 
dinucleotides, predicting exactly how the mutations affect the splicing is difficult and 
would be more accurately determined via functional studies, such as determining the 
structure of the resulting protein.   
Moreover, the presence of the different types of mutations in the fish is curious. 
Why did some of them receive the double insertion while others have the “TG” gap? Some 
of this might best be explained by scientific variability, whether it be in the fish themselves 
or the handling of them. In respect to the “TG” gap, it is possible that homology directed 
repair just never happened. After the cut was induced via the CRISPR/Cas9 system, 
perhaps the stop cassette oligonucleotide was not proximal to the site so cut sequence was 
eventually ligated back together after a few nucleotides were chewed off on either end.  
Finally, of course when using a CRISPR/Cas9 system, the guide RNA must be 
carefully and precisely designed to ensure the lowest possible chance of off-target affects. 
ChopChop105, the tool that was used to generate the oligonucleotide sequences uses an 
internal algorithm that rates the specificity of the sgRNA. Furthermore, to verify this, we 
aligned the sgRNA sequence “GGACTCCAGCCTGAACACAG” against the GRCz11 
zebrafish assembly using BLAT and only found one match – suggesting proper design of 
the sgRNA. Thus, off-target affects are minimal.  
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After all this, the characteristic mutation search results were our attempt to 
incorporate our findings from the PCR into the previously collected RNA Sequencing data. 
The goal was to determine if mutation types could explain the variability in phenotype in 
the fish. What we found is that there only seems to be a small association with the stop 
cassette mutation type in the 4dpf severe mutants. They appear to have a higher percentage 
of “double partial insertions” and a lower percentage of “TG” gaps – suggesting that 
perhaps the increase in severity (as compared to the mild mutants) is partially explained by 
the different types of mutations. However, after searching for a short fragment of exon 2 
or 3 in the reads matching the mutation types, this trend seems to disappear, making us 
question whether or not the reads are from gmppb, or if they are in fact reads from a 
different region of the genome. In order to investigate this, a more robust method of 
validating the location of the reads would need to be used, likely with a method other than 
grep. Furthermore, to really understand the effect of the DNA changes on the processed 
mRNA transcript and subsequent translated amino acid sequence, a tool that can identify 
intron/exon boundaries of zebrafish transcripts is needed. This would allow for prediction 
of protein products which could be confirmed via protein isolation from mutants and amino 
acid identification.  
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APPENDIX A: COMPARISON OF MUSCULAR DYSTROPHY TYPES 
Table A1. The nine main forms of MD106. 
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APPENDIX B – SCRIPTS  
B1 Identifying predominantly expressed miRNA 
#Grace Smith. 1/16. This code will determine which miRNA end (5' or 3') is more highly 
expressed 
setwd("File/Path") 
 
# Read in miRNA expression data 
counts <- read.table("all_counts_normalized.txt",sep="\t",header=T) 
counts[is.na(counts)] <- 0 
 
#make lists of each of the arms 
counts_5p <- counts[1,]  
counts_3p <- counts[2,] 
 
#add the rows based on the 2nd column containing either 3p or 5p  
for (i in 3:550) 
  if (any(grepl("3p", counts[i,2])))  
  { counts_3p <- rbind(counts_3p, counts[i,])  
  } else {  
      counts_5p <- rbind(counts_5p, counts[i,]) } 
 
#write the tables 
write.table(counts_3p, "3p_counts.txt", sep="/t") 
write.table(counts_5p, "5p_counts.txt", sep="/t") 
 
#change the column names of each 
colnames(counts_5p) <- c("miRNA", "arm", "SIB4_5p", "MIL4_5p", "SEV4_5p", 
"SIB7_5p", "MIL7_5p", "SEV7_5p") 
colnames(counts_3p) <- c("miRNA", "arm", "SIB4_3p", "MIL4_3p", "SEV4_3p", 
"SIB7_3p", "MIL7_3p", "SEV7_3p") 
 
#now I want to compare the expression of the two arms 
merged <- merge(counts_3p, counts_5p, by.x=1, by.y=1, all.x=TRUE, all.y=TRUE) 
data <- merged[3:8]   
data <- cbind(data, merged[10:15]) 
row.names(data) <- merged[,1] 
data[is.na(data)] <- 0 
 
avg <- data.frame(rowSums(data[1:6])) 
avg <-  cbind(avg, rowSums(data[7:12])) 
row.names(avg) <- merged[,1] 
colnames(avg) <- c("3p", "5p")  
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avg <- cbind(avg, (avg$`3p`-avg$`5p`)) 
#now, if 5p is higher, col3 = -; if 3p is higher col3 = +!!!!! 
sum(avg[3]>0) #number 3p miRNAs that are expressed strand 
sum(avg[3]<0) #number 5p miRNAs that are expressed strand 
 
 
#now I want to write a file that only contains the predominantly expressed miRNAs and 
not the passengers 
predom_miRNA <- data.frame(merged[,1], stringsAsFactors=FALSE) 
 
for (i in 1:287) 
  if (avg[i,3]>0) { 
    predom_miRNA[i,2] <- "3p" 
    } else { 
    predom_miRNA[i,2] <- "5p" } 
 
colnames(predom_miRNA) <- c("miRNA", "arm") 
p <- data.frame(predom_miRNA[,2]) 
row.names(p) <- predom_miRNA[,1] 
write.table(p, "predominantly_expressed_miRNA_arm.txt", sep="") 
 
#in excel I made a file that has the correct labels and then miRNAs with and without a * 
at the end 
a <- read.table("predominantly_expressed_miRNA_arm_passenger.txt", header=T) 
b <- merge(a, counts[,2], by.x=1, by.y=1) 
write.table(b, "labeled_predominantly_expressed_miRNA_arm.txt", row.names=F) 
 
sum(grepl("\\*", b$predom_miRNA)) 
#tells you that 22 of the miRNAs that are predominantly expressed were labeled as 
passengers!     
 
B2 Repeat Masker analysis to identify candidate lncRNAs 
#Grace Smith 1/23: Script reads in repeat masked files, calculates % repetitive bases 
 
library(stringr) 
setwd("Folder") 
filenames <- list.files(pattern="masked.txt")  #repeat masked files to read in 
 
all_transcripts <- data.frame("ID", "total_bases", "repetitive_bases", "ratio_rep_bases") 
colnames(all_transcripts) <- c("ID", "total_bases", "repetitive_bases", "ratio_rep_bases") 
 
for (f in 1:length(filenames)) 
{ 
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    b <- read.table(filenames[f], sep="\t", header=F) 
    A=N=0  
    for (i in 1:nrow(b)) 
      { 
        if (grepl(">", b[i,1]))     #means new transcript encountered 
          { 
            if (i==1 & f==1)  
            { 
              tran <- grep("MSTRG.\\d*.\\d*", b[i,1], value=T)   #if 1st row & 1stfile, do 
nothing 
            } else { 
                new <- data.frame(tran, A, N, (N/A)) 
                colnames(new) <- c("ID", "total_bases", "repetitive_bases", "ratio_rep_bases") 
                all_transcripts <- rbind(new, all_transcripts) 
                tran <- grep("MSTRG.\\d*.\\d*", b[i,1], value=T)   #get next id 
                A = N = 0    #reset parameters 
            } 
          } else { 
            A = A+str_count(b[i,1]) 
            N = N+str_count(b[i,1], "N") 
          } 
    } 
    ###if the end of file is reached, add the final row 
    new <- data.frame(tran, A, N, (N/A)) 
    colnames(new) <- c("ID", "total_bases", "repetitive_bases", "ratio_rep_bases") 
    all_transcripts <- rbind(new, all_transcripts) 
    A=N=0 
} 
 
write.table(all_transcripts, "4dpf_Severe_ratio_repeat_masked_bases_adj_P.txt", 
sep="\t") 
 
Threshold <- 0.6 
threshold_transcript <- subset(all_transcripts, 
(all_transcripts$ratio_rep_bases<Threshold)) 
name <- paste(Threshold, 
"Threshold_4dpf_Severe_ratio_repeat_masked_bases_adj_P.txt", sep="_") 
write.table(threshold_transcript, name, sep="\t") 
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